Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of mNEXSPIKE, a new COVID vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 years and older. Following the CHMP’s positive opinion, the European Commission will make a marketing authorization decision.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts
- Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls
- Moderna price target lowered to $28 from $30 at Morgan Stanley
- Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating
- Moderna initiated with a Hold at Jefferies